the disclosure, combination therapy comprising a Jinashikuribu antagonists and CDK inhibitor of programmed death 1 receptor (PD-1), for the treatment of cancer, in particular, the cancers that express PD-L1 treatment It describes the use of combination therapy forFIELD 8A